Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS
Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas
Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma
Defining breast cancer quality care around the globe
Global oncology innovations: B.J. Kennedy award for geriatric oncology
Global disparities in cancer care for conflict-affected populations: Africa's neglected crisis
Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC
The evolving treatment landscape in immune thrombocytopenia
Highlights from APCCC 2026
ASCO 2026: Updates in bladder cancer
ASCO 2026: Updates in renal cancer
ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer